USPTO serial 88902307
DETECT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRIEDMAN, LESLEE ANN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DETECT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer S. Stachniak
Jennifer S. Stachniak JOHNSON, MARCOU, ISAACS & NIX, LLCP.O. BOX 691HOSCHTON, GA 30548United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations for scientific or research use; Reagent paper other than for medical purposes | ACTIVE | — |
| 005 | RNA-guided therapeutic pharmaceuticals for the treatment of diseases and medical conditions, namely, allergies, autoimmune diseases and disorders, autoinflammatory diseases and disorders, bacterial infections, mycoses, blood diseases and disorders, cancer, cardiovascular diseases and disorders, chromosomal diseases and disorders, congenital diseases and abnormalities, hereditary diseases and abnormalities, neonatal diseases and abnormalities, cognitive diseases and disorders, connective tissue diseases and disorders, digestive system diseases and disorders, diabetes, ear, nose, and throat diseases and disorders, endocrine system diseases and disorders, female urogenital diseases and disorders, female reproductive diseases and disorders, pregnancy complications, fungal infections, genetic diseases and disorders, gastro-intestinal diseases and disorders, hemic and lymphatic diseases and disorders, hereditary cancer syndromes, heart diseases and disorders, hormonal diseases and disorders, immune system diseases and disorders, immunodeficiency diseases and disorders, infectious disease, inflammatory diseases and disorders, kidney and urinary diseases and disorders, lung diseases and disorders, male reproductive diseases and disorders, male urogenital diseases and disorders, mouth diseases and disorders, musculoskeletal diseases and disorders, neoplasms, nervous system diseases and disorders, neurological diseases and disorders, neuropsychiatric diseases and disorders, nutritional and metabolic diseases, ocular diseases and disorders, otorhinolaryngologic diseases, parasitic infections, respiratory diseases and disorders, skin and connective tissue diseases, stomatognathic diseases and disorders, chemical imbalances, viral infections; diagnostic preparations for medical or veterinary purposes; Reagent paper for medical or veterinary purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, allergies, autoimmune diseases and disorders, autoinflammatory diseases and disorders, bacterial infections, mycoses, blood diseases and disorders, cancer, cardiovascular diseases and disorders, chromosomal diseases and disorders, congenital diseases and abnormalities, hereditary diseases and abnormalities, neonatal diseases and abnormalities, cognitive diseases and disorders, connective tissue diseases and disorders, digestive system diseases and disorders, diabetes, ear, nose, and throat diseases and disorders, endocrine system diseases and disorders, female urogenital diseases and disorders, female reproductive diseases and disorders, pregnancy complications, fungal infections, genetic diseases and disorders, gastro-intestinal diseases and disorders, hemic and lymphatic diseases and disorders, hereditary cancer syndromes, heart diseases and disorders, hormonal diseases and disorders, immune system diseases and disorders, immunodeficiency diseases and disorders, infectious disease, inflammatory diseases and disorders, kidney and urinary diseases and disorders, lung diseases and disorders, male reproductive diseases and disorders, male urogenital diseases and disorders, mouth diseases and disorders, musculoskeletal diseases and disorders, neoplasms, nervous system diseases and disorders, neurological diseases and disorders, neuropsychiatric diseases and disorders, nutritional and metabolic diseases, ocular diseases and disorders, otorhinolaryngologic diseases, parasitic infections, respiratory diseases and disorders, skin and connective tissue diseases, stomatognathic diseases and disorders, chemical imbalances, viral infections; Medical diagnostic reagents and assays for testing of body fluids | ACTIVE | — |
| 044 | Disease and pest control treatments for agriculture, namely, breeding and propagating genetically modified plants with increased disease resistance; performing diagnosis of diseases; Medical testing for diagnostic or treatment purposes; Providing medical information from a website; Providing a website featuring information in the field of the diagnosis and treatment of allergies, autoimmune diseases and disorders, autoinflammatory diseases and disorders, bacterial infections, mycoses, blood diseases and disorders, cancer, cardiovascular diseases and disorders, chromosomal diseases and disorders, congenital diseases and abnormalities, hereditary diseases and abnormalities, neonatal diseases and abnormalities, cognitive diseases and disorders, connective tissue diseases and disorders, digestive system diseases and disorders, diabetes, ear, nose, and throat diseases and disorders, endocrine system diseases and disorders, female urogenital diseases and disorders, female reproductive diseases and disorders, pregnancy complications, fungal infections, genetic diseases and disorders, gastro-intestinal diseases and disorders, hemic and lymphatic diseases and disorders, hereditary cancer syndromes, heart diseases and disorders, hormonal diseases and disorders, immune system diseases and disorders, immunodeficiency diseases and disorders, infectious disease, inflammatory diseases and disorders, kidney and urinary diseases and disorders, lung diseases and disorders, male reproductive diseases and disorders, male urogenital diseases and disorders, mouth diseases and disorders, musculoskeletal diseases and disorders, neoplasms, nervous system diseases and disorders, neurological diseases and disorders, neuropsychiatric diseases and disorders, nutritional and metabolic diseases, ocular diseases and disorders, otorhinolaryngologic diseases, parasitic infections, respiratory diseases and disorders, skin and connective tissue diseases, stomatognathic diseases and disorders, chemical imbalances, viral infections | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by The Broad Institute, Inc.
- Other trademarks owned by The Broad Institute, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named DETECT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 8, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 8, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 23, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 12, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 11, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 11, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 1, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 1, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 2, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 28, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 28, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 28, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 3, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 1, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 1, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 1, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 10, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 8, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 8, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 8, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 28, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 26, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 26, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 26, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 2, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 21, 2021 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Oct 7, 2020 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 8, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 8, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 5, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 5, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 5, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 5, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 5, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 29, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 25, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 25, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 25, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 19, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| May 17, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 8, 2020 | NWAP | NEW APPLICATION ENTERED | — |